We have now shown that hepatic FASN deficiency ameliorated NAFLD and diabetes in Mc4r-KO mice by suppressing DNL, FAO, and gluconeogenesis and improving hepatic insulin signaling without inducing hypertriglyceridemia. The gene discussed is FASN; the disease is metabolic dysfunction-associated steatotic liver disease.